Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,401–9,500 of 15,747
Islam, Z., Yamamoto, S., Mizoue, T., Tanaka, A., Oshiro, Y., Inamura, N., Konishi, M., Ozeki, M., Sugiura, W., & Ohmagari, N. (2022) · Vaccines · doi:10.3390/vaccines10050776 · Cited by 5
“Randomized controlled trials [6,7] have reported that COVID-19 vaccines are highly effective in preventing COVID-19, irrespective of diabetes status.”
BackgroundTantiyavarong, W., Sungkasubun, P., Chaiwiriyawong, W., et al. (2023) · JCO Global Oncology · doi:10.1200/go.22.00331 · Cited by 5
“7) Others 408 [114-702] 4 [3-16] 2/2 (100.”
BackgroundInfluentialTakahashi, K., Samura, O., Hasegawa, A., Okubo, H., Morimoto, K., Horiya, M., Okamoto, A., Ochiai, D., Tanaka, M., Sekiguchi, M., et al. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-05669-4 · Cited by 6
“Our study confirmed that the overall incidence of adverse effects due to mRNA vaccines was higher after the second dose than after the first dose, as reported previously for the general population and pregnant women [2, 27, 28].”
BackgroundResultAlahmari, A. K., AlAsmari, A., AlKorbi, A., Ahmed, N. J., Almalki, Z. S., Alshehri, A. M., Albassam, A. A., & Alem, G. M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.06.009 · Cited by 4
Pergent, M., Haerynck, F., Hoste, L., & Gardulf, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166198 · Cited by 7
“Fatigue is the most frequently reported symptom, followed by muscle and/or body pain and headache similar to other studies (9, 10).”
BackgroundResultInfluentialMyocarditis Following COVID-19 Vaccination: A Systematic Review
Shaheen, N., Ramadan, A., Shaheen, A., Elmasry, M., Swed, S., Hafez, W., & Wael, M. (2023) · Cureus · doi:10.7759/cureus.37999 · Cited by 8
“Both of the initial studies to establish the efficacy of mRNA vaccines did not report any cases of myocarditis [6,7].”
ResultLang, A.-L., Hohmuth, N., Višković, V., Konigorski, S., Scholz, S. M., Balzer, F., Remschmidt, C., & Leistner, R. (2024) · Journal of Medical Internet Research · doi:10.2196/47070 · Cited by 5
“By contrast, in a multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, VE against infection of any severity stayed at >90% at 24 weeks after the second vaccine dose [34].”
ResultPantoja, C., Acosta, F. M., Granatir, S., Anderson, M., Wyr, M., Tailor, J., Fuori, A., Dower, W. J., Marr, H. B., & Ramirez, P. W. (2025) · Scientific Reports · doi:10.1038/s41598-025-01896-1 · Cited by 5
Joseph, G., Cohen, C., Rubin, C., Murad, H., Indenbaum, V., Asraf, K., Weiss-Ottolenghi, Y., Segal‐Lieberman, G., Kreiss, Y., Lustig, Y., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11071628 · Cited by 7
“to stop the spread of the disease [2].”
BackgroundDevelopment of Digital Learning Simulators to Increase Vocational Students' Prior Knowledge
Hidayatullah, R. S., Supardji, S., & Susila, I. W. (2024) · TEM Journal · doi:10.18421/tem133-26 · Cited by 14
Malysheva, N., Wang, J., & von Kleist, M. (2022) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2022035 · Cited by 5
Hébert, M., Bouhout, S., Vadboncoeur, J., & Aubin, M. (2022) · Vaccines · doi:10.3390/vaccines10101692 · Cited by 5
Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
Gyang, T. V., Evans, J. P., Miller, J. S., Alcorn, K., Peng, J., Bell, E. H., Zeng, C., Gumina, R. J., Liu, S., & Segal, B. M. (2022) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173221087357 · Cited by 5
Radiology, COVID-19, and the next pandemic
Weisberg, E. M., Chu, L. C. H., Rowe, S. P., & Fishman, E. K. (2021) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2021.07.004 · Cited by 4
Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in LungTransplant Patients
van Gemert, J. P., Steenberg, F., van Leer‐Buter, C., Kerstjens, H. A. M., Steenhuis, W. N., Akkerman, O. W., Verschuuren, E. A. M., & Gan, C. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124125 · Cited by 4
“However, most of the initial trials excluded solid organ transplant (SOT) patients [1,3,5].”
BackgroundInfluentialPakhchanian, H. H., Raiker, R., Wolf, M., & Trotter, S. C. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21038 · Cited by 6
Supportive Care for Patients With Myelodysplastic Syndromes
Stempel, J. M., Podoltsev, N. A., & Dosani, T. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000661 · Cited by 6
Suzuki, T., Asai, Y., Tsuzuki, S., Nomoto, H., Matsunaga, N., Kodama, E. N., Hayakawa, K., & Ohmagari, N. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.12.002 · Cited by 4
COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis
Pakhchanian, H. H., Saud, A., Raiker, R., Kardeş, S., Aggarwal, R., & Gupta, L. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06081-7 · Cited by 5
The Politics of Vaccine Hesitancy in the United States
(2021) · doi:10.1101/2021.12.01.21267160 · Cited by 5
“Pfizer released the first interim results from their Phase 3 clinical trial in a press release on November 9, 2020,(4) and published the results on December 31, 2020 (Polack et al., 2020).”
Gonçalves, N. V., Leal, A. L., Guimarães, H. M. M. E. S., BERNARDES, A. C., de Brito, S. R., Alves, T. M. K., Filgueiras, T. C. G. M., de Moraes, T. M., Rocha, M. P. D. C., Cardoso, R. F., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318607 · Cited by 9
“Information related to vaccination coverage, filled in correctly in the disease notification systems, has thus been important in reducing the severity of the disease, especially in populations with the risk factors discussed above, linked to age and the presence of comorbidities [36,37].”
Shang, Y., Wu, J., Liu, J., Long, Y., Xie, J., Zhang, D., Hu, B., Zong, Y., Liao, X., Shang, X., et al. (2022) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2022.07.001 · Cited by 5
Meah, S., Shi, X., Fritsche, L. G., Salvatore, M., Wagner, A. L., Martin, E. T., & Mukherjee, B. (2023) · Science Advances · doi:10.1126/sciadv.adj3747 · Cited by 7
Wen, G., Zhu, M., Li, L., Li, X., Ye, H., & Zhou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1099629 · Cited by 6
“1% protection against symptomatic Covid-19 (4), lower than that of the mRNA Covid-19 vaccine (44).”
BackgroundBurn, E., Li, X., Delmestri, A., Jones, N., Duarte‐Salles, T., Reyes, C., Martínez‐Hernández, E., Martí, E., Verhamme, K. M. C., Rijnbeek, P. R., et al. (2021) · medRxiv · doi:10.1101/2021.07.29.21261348 · Cited by 5
(2021) · doi:10.1101/2021.09.28.21264245 · Cited by 22
Alonso, R., Gil-Manso, S., Catalán, P., Sánchez-Arcilla, I., Marzola, M., Correa‐Rocha, R., Muñóz, P., Pion, M., & the Gregorio Marañón Microbiology-ID COVID-19 Study Group (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341313 · Cited by 5
Unraveling the Role of Ionizable Lipid Isomerism in Modulating Lipid Nanoparticles for mRNA Delivery
He, Z., Liu, Z., Zuo, T., Gao, Z., Yang, H., Zhang, Z., Chu, Y., Li, Z., Ge, X., Pan, X., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c20438 · Cited by 6
Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines
(2021) · doi:10.1101/2021.06.15.21256661 · Cited by 5
“Comirnaty is reported to be 95% effective in 45 preventing symptomatic COVID-19 with low incidence of serious adverse events (5).”
Optimizing Patient Recruitment in Global Clinical Trials using Nature-Inspired Metaheuristics
Schepps, M. A., Wong, W. K., Austin, M., & Anisimov, V. V. (2024) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2024.2308882 · Cited by 6
“…in 99 clinical trial sites in the United States, the Pfizer Phase III trial which recruited 43,548 patients in 152 sites in six countries, and the Johnson & Johnson Phase III trial which recruited 43,783 patients in eight countries (Polack et al. 2020; Baden et al. 2021; Sadoff et al. 2021).”
Post-COVID-19 Vaccination Infection Among Adults in Saudi Arabia: A Cross-Sectional Study
Mohammed, R. A., Baqais, O. A., Basalib, S. G., Owaidah, A. A., Mirza, A. A., Al-Harizy, R. M., & Sultan, I. E. (2023) · Cureus · doi:10.7759/cureus.47552 · Cited by 5
“Another explanation is that the presence of systemic reactions after vaccination can enhance testing for COVID-19 in the first few days after vaccination [10].”
BackgroundMessenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 6
“At the first interim analysis, after 2 months of median follow up, 8 cases of PCR confirmed COVID-19 were seen in the BNT162b2 recipients (7 days after second dose), whereas 162 cases of PCR confirmed COVID-19 were seen in the placebo group.(57) This resulted in a VE of 95% (95% CI, 90.”
BackgroundMethodResultInfluentialRaj, P. R., Adler, P. A., Chalasani, R., & Wan, S. L. (2022) · Seminars in Ophthalmology · doi:10.1080/08820538.2022.2082255 · Cited by 5
“pain at the injection site, fatigue, headache and myalgia).(3) However, serious systemic reactions, including anaphylaxis, are rare with overall incidences of 0.”
BackgroundAbt, E. R., Lam, A. K., Noguchi, M., Rashid, K., McLaughlin, J., Teng, P.-L., Tran, W., Cheng, D., Nesterenko, P. A., Mao, Z., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406332121 · Cited by 6
“Nucleoside - modified mRNA encapsulated in lipid nanoparticles containing ionizable lipids (mRNA - iLNP) has emerged as a powerful viral vaccine platform to elicit cellular and antibody - mediated immunity ( 14 – 16 ).”
Polysorbate 80-containing ionizable lipid nanoparticles for mRNA delivery
Tang, X., Ding, S., Yang, S., Cheng, Y., Liu, H., Chen, K., & Han, X. (2024) · Biomaterials Science · doi:10.1039/d4bm00523f · Cited by 5
Nevermann, N., Wiering, L., Wu, H., Moroder, P., Brandl, A., Globke, B., Krenzien, F., Raschzok, N., Schöning, W., Lurje, G., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13696 · Cited by 5
Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Couto, C. I. C., Güler, A., Mampilli, V., Schmitt, G. J., Mottl, J., et al. (2022) · bioRxiv · doi:10.1101/2022.09.21.508818 · Cited by 3
Self-citationCOVID-19 Vaccination Limits Systemic Danger Signals in SARS-CoV-2 Infected Patients
Angioni, R., Sasset, L., Cioccarelli, C., Sánchez‐Rodríguez, R., Bertoldi, N., Putaggio, C., Viola, A., Cattelan, A. M., & Molon, B. (2022) · Viruses · doi:10.3390/v14030565 · Cited by 5
Sanna, G., Marongiu, A., Firinu, D., Piras, C., Franci, G., Galdiero, M., Pala, G., Palmas, V., Angius, F., Littera, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10040531 · Cited by 6
“Many of those currently approved by The European Medicines Agency (EMA) provide for the inoculation of two doses after a set time to enhance the antibody response [7,8].”
BackgroundHerpetic anterior uveitis following COVID-19 vaccines: a case series
Ott, M., Nagamany, T., Zandi, S., Pichi, F., Agarwal, A. K., Carreño, E., Gupta, V., Grewal, D. S., Cunningham, E. T., & Munk, M. R. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1242225 · Cited by 6
“This raises the question of a possible lack of reporting or a very low incidence of ocular events (6, 7, 38, 39).”
BackgroundHuete‐Carrasco, J., Zhu, J., den Eynde, B. J. V., Mayer, C. T., Sparwasser, T. D., Ward, R. W., & Lavelle, E. C. (2025) · Immunology and Cell Biology · doi:10.1111/imcb.70049 · Cited by 7
Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea
Gwak, E., Choe, S., Kim, K., Bolormaa, E., Fix, J., Vadivale, M., Rousculp, M. D., & Choe, Y. J. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127496 · Cited by 3
mRNA Vaccines Induce Rapid Antibody Responses in Mice
(2021) · doi:10.1101/2021.11.01.466863 · Cited by 5
“Furthermore, 40 clinical trials have now shown the rapid protective efficacy of mRNA vaccines post prime 41 immunizations [5, 6].”
BackgroundMethodSzakó, L., Farkas, N., Kiss, S., Váncsa, S., Zádori, N., Vörhendi, N., Erőss, B. M., Hegyi, P., & Alizadeh, H. (2021) · Trials · doi:10.1186/s13063-021-05066-2 · Cited by 7
Simple Scattering: Lipid nanoparticle structural data repository
Kim, L. J., Shin, D. S., Leite, W. C., O’Neill, H., Ruebel, O., Tritt, A., & Hura, G. L. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1321364 · Cited by 5
Kumar, A., Ladha, A., Choudhury, A., Ikbal, A. M. A., Bhattacharjee, B., Das, T., Gupta, G., Sharma, C., Sarbajna, A., Mandal, S. C., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2081156 · Cited by 6
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
Wei, X., Rong, N., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993754 · Cited by 6
Sun, T., Li, L., Mues, K. E., Georgieva, M. V., Kirk, B., Mansi, J. A., de Velde, N. V., & Beck, E. C. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01005-1 · Cited by 6
“The safety and efficacy of two doses of both mRNA-1273 and BNT162b2 in reducing the risk of SARS-CoV-2 infection and of severe outcomes from COVID-19 in the general population and in adolescents has been demonstrated in phase 3 clinical trials [3–5].”
Glatman‐Freedman, A., Feldman, S. F., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan‐Boker, L., & Bromberg, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac524 · Cited by 6
Lee, Y., Jeong, S. A., Park, H. C., Kim, D. H., Yoo, K. D., Yoon, H. E., Kim, Y., & Cho, A. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1372525 · Cited by 5
Yoshino, Y., & Ishida, T. (2023) · Cureus · doi:10.7759/cureus.37480 · Cited by 5
“This vaccine to prevent the development of coronavirus infection 2019 (COVID-19) was developed through large-scale clinical trials [1].”
Akinyemi, P. A., Owoade, I. A., Fajobi, O., Wuraola, F. O., & Elugbaju, O. (2021) · Journal of Community Medicine and Primary Health Care · doi:10.4314/jcmphc.v33i2.1 · Cited by 5
González, S. E., Olszevicki, S., Gaiano, A., Varela, A. N., Regairaz, L., Salazar, M. R., Pesci, S. A., Marín, L., González, V., Varela, T., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4087375 · Cited by 5
D’haese, S., den Roover, S., Verbeke, R., Aernout, I., Meulewaeter, S., Cosyns, J., Meert, J., Vanbellingen, S., Laeremans, T., Lentacker, I., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102372 · Cited by 6
Borkens, Y. (2023) · Acta Parasitologica · doi:10.1007/s11686-023-00712-y · Cited by 8
Patel, P., Kaushik, N., Acharya, T. R., Lenka, S. S., Ghosh, S., Wahab, R., Verma, S. K., Choi, E. H., & Kaushik, N. K. (2024) · Advanced Science · doi:10.1002/advs.202411515 · Cited by 6
Autore, F., Stirparo, L., Innocenti, I., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897937 · Cited by 5
“Since December 2020, several vaccine platforms against SARS-CoV-2 have been developed with a high efficacy and safety profile (4, 5).”
BackgroundArcangeli, A., Ralli, M., De‐Giorgio, F., Soave, P. M., & Ercoli, L. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-020-00633-1 · Cited by 5
(2021) · doi:10.1101/2021.11.05.21265961 · Cited by 5
“The observed increase in adverse events compared with earlier doses could be due to a stronger response elicited by the 3 dose, comparable to what was observed for the 2 dose compared with the 1 dose.(1,2,33) Further studies are needed to explore whether the 3 vaccine dose does indeed induce a stronger immune response.”
Kumar, K., Tan, W. S., Arshad, S. S., & Ho, K. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054398 · Cited by 6
“The efficacies of these vaccines were between 70 to 95% against SARS-CoV-2 infection [1,2].”
BackgroundJiang, J., Lau, E. H. Y., Zhou, Z., Yin, G., Lin, Y., Cowling, B. J., & Lam, K. F. (2024) · Vaccines · doi:10.3390/vaccines12091014 · Cited by 6
Tane, M., Kosako, H., Sonoki, T., & Hosoi, H. (2024) · Biomedicines · doi:10.3390/biomedicines12061287 · Cited by 8
“There were no mentions of adverse events related to TAFRO syndrome or iMCD in either the package inserts of COVID-19 vaccines or the reports of the clinical trials for COVID-19 vaccines [73,74].”
BackgroundThe effect of mixed vaccination rollout strategy: A modelling study
Stollenwerk, N., Estadilla, C. D. S., Mar, J., Van-Dierdonck, J. B., Ibarrondo, O., Blasco-Aguado, R., & Aguiar, M. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.03.002 · Cited by 6
“Vaccines against COVID-19 have been developed in record time (Baden et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021) with emergency use authorization granted as early as December 2020.”
Boosting with updated COVID-19 mRNA vaccines
Bhattacharya, D., & Victora, G. D. (2022) · Nature Medicine · doi:10.1038/s41591-022-02048-y · Cited by 5
Declercq, J., Tobback, E., Vanhee, S., et al. (2021) · Allergy · doi:10.1111/all.15101 · Cited by 5
Update on andrological effects of SARS‐CoV‐2 infection and COVID‐19: An overview review
Lisco, G., Tullio, A. D., Matin, M., et al. (2024) · Andrology · doi:10.1111/andr.13830 · Cited by 5
Takagi, A., & Matsui, M. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01659-21 · Cited by 5
“1 (1) (Thermo Fisher Scientific, MA) (pcDNA3.”
BackgroundInfluentialNOTTO COVID-19 Vaccine Guidelines for Transplant Recipients
Kute, V. B., Agarwal, S. K., Prakash, J., Guleria, S., Shroff, S., Sharma, A., Varma, P. P., Prasad, N., Sahay, M., Gupta, S. C., et al. (2021) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_2_21 · Cited by 5
Non‐Viral RNA Delivery During Pregnancy: Opportunities and Challenges
Chaudhary, N., Newby, A. N., & Whitehead, K. A. (2023) · Small · doi:10.1002/smll.202306134 · Cited by 13
A Review on Circular RNA Translation and Its Implications in Disease
Wei, H. Y., Fan, X., & Mao, M. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4290-0_5 · Cited by 6
Imanishi, I., Asahina, R., Hayashi, S., Uchiyama, J., Hisasue, M., Yamasaki, M., Murata, Y., Morikawa, S., Mizutani, T., & Sakaguchi, M. (2022) · BMC Veterinary Research · doi:10.1186/s12917-022-03527-7 · Cited by 5
“SARSCoV-2 infections have become widespread [2], even in vaccinated individuals [3, 4].”
BackgroundWan, E. Y. F., Wang, B., Lee, A. L., Zhou, J., Chui, C. S. L., Lai, F. T. T., Li, X., Wong, C. K. H., Hung, I. F., Lau, C. S., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107149 · Cited by 5
Thomas, R., Zaqout, A., Meqbel, B., Jafar, U., Vaikath, N. N., Aldushain, A., Naik, A., Shaath, H., Al-Akl, N. S., Adam, A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557426 · Cited by 5
Limper, U., Defosse, J., Schildgen, O., & Wappler, F. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.03.007 · Cited by 7
Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · medRxiv · doi:10.1101/2022.01.25.22269735 · Cited by 8
Simulating the impact of different vaccination policies on the COVID-19 pandemic in New York CityPreprint
Yang, W., Kandula, S., & Shaman, J. L. (2021) · medRxiv · doi:10.1101/2021.01.21.21250228 · Cited by 5
A spleen-targeted vaccine for SARS-CoV-2 — Inducting neutralizing antibodies in mice
Shimizu, T., Abe, S., Kawaguchi, Y., Takata, H., Ando, H., & Ishida, T. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.01.024 · Cited by 5
Catch me if you can: viral nucleic acids to host sensors
Jung, Y., Grainger, H., Yang, S., Mondal, S., Lukong, K. E., Conn, K. L., & Wu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1632283 · Cited by 8
Emerging Landscape of Preclinical Models for Studying COVID-19 Neurologic Diseases
Li, J., Wang, J., & Wang, H. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00127 · Cited by 5
Chan, B. C.-L., Li, P., Tsang, M. S., Sung, J. C.-C., Kwong, K. W.-Y., Zheng, T., Hon, S. S.-M., Lau, C.-P., Ho, R. C.-Y., Chen, F., et al. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad106 · Cited by 4
Self-citationPape, K. A., Dileepan, T., Matchett, W. E., Ellwood, C., Stresemann, S., Kabage, A. J., Kozysa, D., Evert, C., Matson, M., Lopez, S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159618 · Cited by 6
“Thirty healthy volunteers and 42 patients with IBD on immunosuppressive therapies, all SARS-CoV-2-naive, were followed at the time of and up to 6 months after vaccination with BNT162b2 (Pfizer-BioNTech) (40) or mRNA-1273 (Moderna) (41) mRNA vaccines.”
BackgroundEncapsulating In Vitro Transcribed circRNA into Lipid Nanoparticles Via Microfluidic Mixing
Juchem, M., Cushman, S., Lu, D., Chatterjee, S., Bär, C., & Thum, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3678-7_14 · Cited by 8
Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., Auewarakul, C. U., & Mahanonda, N. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2099380 · Cited by 6
Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventionsPreprint
Kraay, A. N. M., Gallagher, M., Ge, Y., Han, P., Baker, J. M., Koelle, K., Handel, A., & Lopman, B. A. (2021) · medRxiv · doi:10.1101/2021.03.12.21253481 · Cited by 6
Variants of SARS Coronavirus-2 and Their Potential Impact on the Future of the COVID-19 Pandemic
Li, X., To, K. K., & Yuen, K. (2021) · Zoonoses · doi:10.15212/zoonoses-2021-1003 · Cited by 5
Huang, Y., Pang, S., Li, L., Do, C. W., Luo, Q., 郑宗立, & Xiong, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114499 · Cited by 12
Expansion of droplets during speaking and singing in Japanese
Kato, H., Okamoto, R., Miyoshi, S., Noguchi, S., Umeda, M., & Chiba, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272122 · Cited by 6
“Furthermore, considering the effectiveness of vaccines in preventing infection, proactive vaccination is another measure of ensuring safe choral activities [42].”
BackgroundYoshimoto, N., Takura, K., YANAGI, A., et al. (2022) · In Vivo · doi:10.21873/invivo.12800 · Cited by 5
Future prospects in mRNA vaccine development
Mbatha, L. S., Akinyelu, J., Maiyo, F., & Kudanga, T. (2023) · Biomedical Materials · doi:10.1088/1748-605x/aceceb · Cited by 8
“Currently, COVID-19 poses a grave threat to global public health and safety and its outbreak has since been declared a pandemic by the World Health Organization, WHO, 2022.”
BackgroundMethodInfluentialColston, K. J., Monsalve, S. C., & Schneebeli, S. T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00348 · Cited by 7
Kennedy, A. B., Mitcham, A., Parris, K., Albertson, F., Ferrer, L. S., O'Boyle, C., Patel, M. K., Gartner, T., Broomer, A. M., Katzman, E., et al. (2024) · Learning Health Systems · doi:10.1002/lrh2.10410 · Cited by 6
Brunner‐Ziegler, S., Spath, T., Kornek, G. V., König, F., Parschalk, B., Schnetzinger, M., Straßl, R. P., Savic, R., Foit, A., Resch, H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.023 · Cited by 5
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.